Use of subcutaneous epinephrine in addition to standard first-line treatment with short-acting β2-agonist and systemic steroids in children and adolescents with an acute severe asthma exacerbation: a systematic review of randomised controlled trials.
Archives of Disease in Childhood · 2026-07-28 · Systematic review
Abstract
IMPORTANCE: Asthma is a common chronic disease with significant morbidity and mortality. OBJECTIVES: To assess the safety and efficacy of subcutaneous epinephrine in addition to the standard first-line treatment of acute asthma in children. DATA SOURCE AND STUDY SELECTION: The following databases were inspected from 1966 to 22 June 2025: MEDLINE, EMBASE, CINAHL and the Cochrane Central Register of Controlled Trials. Only randomised controlled trials were included. DATA EXTRACTION AND SYNTHESIS: One study out of 197 citations was included in this review. MAIN OUTCOMES: The outcome measures were morbidity, escalation of care, length of hospital stay, adverse events, mortality due to exacerbation and change in lung function. RESULTS: We included one study with a total number of participants (n)=43. Participants who received subcutaneous epinephrine showed no significant difference in the asthma clinical score postintervention (3.3 compared with 4.0, respectively), as well as in the hospitalisation rate (risk ratio (RR) 0.38, 95% CI 0.04 to 3.40, p=0.39, n=43) and the need for additional intravenous medications (RR 0.23, 95% CI 0.03 to 1.81, p=0.16, n=43), or predicted increase in peak expiratory flow (PEF) percentage at 2 hours (mean difference -1.00, 95% CI -8.21 to 6.21, p=0.79, n=31). CONCLUSION: This review demonstrated very low certainty of evidence based on a single paper indicating that subcutaneous epinephrine does not benefit children with acute asthma in terms of asthma clinical score, hospitalisation rate and the need for additional intravenous medications. No significant improvement in PEF percentage was observed after the intervention. PROSPERO REGISTRATION NUMBER: CRD42023405407.
Abstract © the authors or publisher, via PubMed. Reuse and removal
Tags
Cardiovascular drugs · Adrenaline · Children
Related articles
- Second-line treatment option for children aged 18 years and under with an acute severe asthma exacerbation: a systematic review and meta-analysis of randomised controlled trials. (Arch Dis Child, 2025)
- Efficacy of low-dose nebulized epinephrine as treatment for croup: A randomized, placebo-controlled, double-blind trial. (Am J Emerg Med, 2019)
- Rational drug use for acute bronchiolitis in emergency care. (Turk J Pediatr, 2017)
- Acute paediatric asthma treatment in the prehospital setting: a retrospective observational study. (BMJ Open, 2023)
- Helium-oxygen therapy for infants with bronchiolitis: a randomized controlled trial. (Arch Pediatr Adolesc Med, 2011)
- Nebulized epinephrine for croup in children. (Cochrane Database Syst Rev, 2013)